---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-012652"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2022-05-05T23:59:59+00:00"
generated_at: "2026-06-25T23:19:20.324860+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Corcept Q1 revenue $93.7M (+18% YoY); reiterates FY2022 guidance $400-430M

## Summary
- Diluted EPS $0.20 vs $0.18 YoY; cash & investments $368.1M (up $32.3M in Q1).
- Phase 3 trial of relacorilant in platinum-resistant ovarian cancer to start this quarter.
- GRATITUDE I/II data for miricorilant in antipsychotic weight gain expected Q4 2022.
- Relacorilant NDA for Cushing's syndrome now expected H2 2023 (pandemic delays).
- Operating expenses $66.9M (+12% YoY) on expanded R&D and legal costs.

## SEC filing metadata
- accession: 0001628280-22-012652
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2022-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828022012652/0001628280-22-012652-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828022012652/cort-20220505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-012652
- JSON: https://secwatch.observer/filing/0001628280-22-012652.json
- Plain text: https://secwatch.observer/filing/0001628280-22-012652.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.